Key immune-related gene ITGB2 as a prognostic signature for acute myeloid leukemia

Jie Wei; Xun-Jun Huang; Yan Huang; Ming-Yue Xiong; Xiang-You Yao; Zhi-Ning Huang; Si-Nian Li; Wei-Jie Zhou; Da-Lang Fang; Dong-Hong Deng; Peng Cheng

doi:10.21037/atm-21-3641

Key immune-related gene ITGB2 as a prognostic signature for acute myeloid leukemia

Ann Transl Med. 2021 Sep;9(17):1386. doi: 10.21037/atm-21-3641.

Authors

Affiliations

¹ Department of Hematology, Baise People's Hospital, Baise, China.
² Department of Breast and Thyroid Surgery, The Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
³ Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China.

Abstract

Background: The tumor microenvironment (TME) has an essential role in tumorigenesis, progression, and therapeutic response in many cancers. Currently, the role of TME in acute myeloid leukemia (AML) is unclear. This study investigated the correlation between immune-related genes and prognosis in AML patients.

Methods: Transcriptome RNA-Seq data for 151 AML samples were downloaded from TCGA database (https://portal.gdc.cancer.gov/), and the immune related genes (irgs) were selected from Immport database. Bioinformatics screening was used to identify irgs for AML, and genes with a critical role in the prognosis of AML were selected for further analysis. To confirm the prognostic role of irgs in AML, we undertook protein-protein interaction (PPI) network analysis of the top 30 interacting genes. We then investigated associations between immune cell infiltration and prognosis in AML patients. Immunohistochemistry was used to validate protein expression levels between AML and normal bone marrow samples. Analysis of the drug sensitivity of the selected gene was then performed.

Results: The integrin lymphocyte function-associated antigen 1 (CD11A/CD18; ITGAL/ITGB2) was identified as the key immune-related gene that significantly influenced prognosis in AML patients. Overexpression of ITGB2 indicated poor prognosis in AML patients (P=0.007). Risk modeling indicated that a high-risk score led to poor outcomes (P=3.076e-08) in AML patients. The risk model showed accuracy for predicting prognosis in AML patients, with area under curve (AUC) at 1 year, 0.816; AUC at 3 years, 0.82; and AUC at 5 years, 0.875. In addition, we found that ITGB2 had a powerful influence on immune cell infiltration into AML TME. The results of immunohistochemistry showed that AML patients had significantly higher ITGB2 protein expression than normal samples. The AML patients were divided into 2 groups based on ITGB2 risk scores. Drug sensitivity test results indicated that the high-risk group was sensitive to cytarabine, axitinib, bosutinib, and docetaxel, but resistant to cisplatin and bortezomib.

Conclusions: In the present study, we found that ITGB2 may be able to serve as a biomarker for assessing prognosis and drug sensitivity in AML patients.

Keywords: Acute myeloid leukemia (AML); ITGB2; tumor microenvironment (TME).